Pharmacokinetics of huperzine A following oral administration to human volunteers

  title={Pharmacokinetics of huperzine A following oral administration to human volunteers},
  author={Y. X. Li and Ran Zhang and C Li and Xiaojuan Jiang},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  • Y. Li, R. Zhang, X. Jiang
  • Published 1 October 2007
  • Biology, Medicine, Chemistry
  • European Journal of Drug Metabolism and Pharmacokinetics
SummaryThe objective of the present study was to investigate the in vivo pharmacokinetics of huperzine A in healthy human volunteers. Twelve subjects (M 6, F 6; age ranged from 20 ∼ 25 years) participated in the study. Huperzine A was administered in tablet form at a single dose of 0.4 mg. Following oral administration, the presence of huperzine A started to appear in the plasma at 5—10 min, and reached the peak concentrations with a Cmax of 2.59±0.37 ng/ml at 58.33±3.89 min (time to reach peak… 

Pharmacokinetics and tolerability of oral dosage forms of huperzine a in healthy Chinese male volunteers: a randomized, single dose, three-period, six-sequence crossover study

  • San-Lan WuJ. Gan Ya-Ni Liu
  • Medicine, Biology
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • 2017
The test and reference products met the regulatory criteria for bioequivalence in these fasting, healthy Chinese male volunteers and all three formulations appeared to be well tolerated.

Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects

A population pharmacokinetic (PPK) model of huperzine A in elderly Chinese subjects is established, which can be used to predict PPK parameters in the treatment of elderly AD patients and was demonstrated to be suitable and effective by the bootstrap and visual predictive checks.

Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder

Time-course and peak effects analyses show that treatment with 0.4mg of huperzine A significantly attenuated cocaine-induced increases of “Any Drug Effect,” “High,’ “Stimulated,‚ “Willing to Pay” and “Bad Effects” (all P>.05).

Treatment with Huperzine A Improves Cognition in Vascular Dementia Patients

Hperzine A can significantly improve the cognitive function in patients with mild to moderate vascular dementia, and the medicament is safe.

Huperzine A as Potential Treatment of Alzheimer's Disease: An Assessment on Chemistry, Pharmacology, and Clinical Studies

Promising data suggested that huperzine A is well tolerated at doses up to 0.4 mg for 24 weeks, and seems to be a potential treatment option for AD.

Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research

HupA provides protection from excitotoxicity and neuronal death as well as increase in GABAergic transmission associated with anticonvulsant activity based on animal studies, and is reviewed as a dietary supplement in the U.S.

Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)

Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents.

Review of HPLC and LC-MS/MS Methods for Determination of ZT-1 and Its Active Metabolite, Huperzine A in Various Biological Matrices

This review provides an overview of various HPLC, LC-MS andLC-MS/MS methods for quantitation of Huperzine A alone or along with ZT-1 in different biological fluids (plasma, serum and blood).

Acetylcholinesterase inhibitors: a patent review (2008 – present)

  • M. Pohanka
  • Biology, Chemistry
    Expert opinion on therapeutic patents
  • 2012
The research for drugs for Alzheimer's disease needs to focus on inhibitors that reduce the deposition of amyloid plaques, but do not initiate AChE expression.



Pharmacokinetics of tablet huperzine A in six volunteers.

Hup-A was absorbed rapidly, distributed widely in the body, and eliminated at a moderate rate according to a one-compartment open model with first order absorption.

[Pharmacokinetics of huperzine A in rats and mice].

Huperzine A, a new alkaloid first isolated in China from Huperzia serratacl), is a reversible cholinesterase inhibitor). Clinical studies have shown that huperzine A can improve muscle weakness of

Determination of huperzine A in cerebrospinal fluid of rats by HPLC-Fluorescence

OBJECTIVE To establish a HPLC-Fluorescence method for the determination of the huperzine A in rat cerebrospinal fluid. METHODS The separation was performed on a ODS-C_(18) column(4.6mm×250mm, 10μm)

Simple determination of huperzine A in human plasma by liquid chromatographic-tandem mass spectrometric method.

The analytical sensitivity and accuracy of this LC-MS-MS method is adequate for characterization of huperzine A in human plasma.

Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat

The study shows that HUP‐A can produce a long‐term inhibition of AChE activity in brain and an increase in the ACh levels up to 40% at 60 min and suggests that this new ChEI has interesting cholinomimetic properties, and its effects satisfy more closely established criteria for an ideal Ch EI for therapeutic use than previously tested compounds.

Liquid chromatographic-tandem mass spectrometric method for the quantitation of huperzine A in dog plasma.

[Effects of huperzine A on learning and the retrieval process of discrimination performance in rats].

The preliminary clinical studies showed that Hup, the first nootropic compound in China, did improve shorter and long-term memory in patients of cerebral arteriosclerosis with memory impairment and suggested that the facilitation actions of Hup were due to an effect on the central cholinergic system.

Huperzine A (shuangyiping): a promising drug for Alzheimer's disease.

  • X. Tang
  • Biology, Chemistry
    Zhongguo yao li xue bao = Acta pharmacologica Sinica
  • 1996
Findings suggest that Hup A is a promising candidate for clinical development as a symptomatic treatment for AD, and has better therapeutic indices, and peripheral cholinergic side effects are minimal at therapeutic doses.

The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity

Huperzine A and B, two new Lycopodium alkaloids isolated from Huperziaserrata (Thunb.) Trev., are shown to possess structures 1 and 3, respectively, on the basis of chemical and spectroscopic data.